{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:41:26Z","timestamp":1773081686756,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nImpulse control disorders (ICD) in Parkinson\u2019s disease (PD) frequently occur, not always as a direct consequence of dopaminergic medication. This study investigated premorbid personality traits and behavioural characteristics in non-demented PD patients with self-reported symptoms of ICD (PD-srICD). From a total of 200 non-demented PD patients who filled out questionnaires assessing symptoms and severity of ICD, those were classified as PD-srICD (<jats:italic>n<\/jats:italic>\u2009=\u200932) who reported current occurrence of at least one compulsive behaviour (gambling, sexual behaviour, buying behaviour, or eating). As a control group, 32 patients with no self-reported ICD symptoms were matched for levodopa equivalent daily dose. The demographic, clinical, and premorbid personality profiles were compared between both groups. Frequency of psychological characteristics indicating substance use disorder was evaluated in patients with PD-srICD. Patients with PD-srICD were more frequently male, younger at examination, had earlier PD onset, more depression, higher non-motor burden, less quality of life (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05, respectively), and more frequently reported premorbid sensation seeking\/novelty orientation (<jats:italic>p<\/jats:italic>\u2009=\u20090.03) and joyful experience of stress (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) than patients in the control group. Of patients with PD-srICD, 90.6% reported at least one behavioural characteristic of substance use disorder, most frequently positive expectations following ICD behaviour and illusional beliefs about its behavioural control. Signs of addiction were common among patients with PD-srICD. Therefore, the profile of psychological characteristics in patients with PD-srICD resembled that of patients with substance use disorder. It can be concluded that dopamine replacement therapy (DRT) alone does not account for PD-srICD and that thorough psychological diagnostics are recommended.<\/jats:p>","DOI":"10.1007\/s00702-023-02588-8","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T19:59:14Z","timestamp":1674244754000},"page":"125-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics of behavioural addiction in Parkinson\u2019s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case\u2013control study"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6976-4194","authenticated-orcid":false,"given":"Bernd","family":"Leplow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Renftle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareike","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Solbrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Maetzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Liepelt-Scarfone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"2","key":"2588_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1360-0443.2010.03218.x","volume":"106","author":"P Ambermoon","year":"2011","unstructured":"Ambermoon P, Carter A, Hall WD, Dissanayaka NNW, O\u2019Sullivan JD (2011) Impulse control disorders in patients with Parkinson\u2019s disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 106(2):283\u2013293. https:\/\/doi.org\/10.1111\/j.1360-0443.2010.03218.x","journal-title":"Addiction"},{"key":"2588_CR2","doi-asserted-by":"publisher","first-page":"e675","DOI":"10.1212\/WNL.0000000000007942","volume":"93","author":"F Baig","year":"2019","unstructured":"Baig F, Kelly MJ, Lawton MA, Ruffmann C, Rolinski M, Klein JC, Barber T, Lo C, Ben-Shlomo Y, Okai D, Hu MT (2019) Impulse control disorders in Parkinson disease and RBD: a longitudinal study of severity. Neurology 93:e675\u2013e687. https:\/\/doi.org\/10.1212\/WNL.0000000000007942","journal-title":"Neurology"},{"key":"2588_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/jnp.12173","volume":"14","author":"S Becker","year":"2020","unstructured":"Becker S, B\u00e4umer A, Maetzler W, Nussbaum S, Timmers M, Van Nueten L, Salvadore G, Zaunbrecher D, Roeben B, Brockmann K, Streffer J, Berg D, Liepelt-Scarfone I (2020) Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson\u2019s patients. J Neuropsychol 14:69\u201384. https:\/\/doi.org\/10.1111\/jnp.12173","journal-title":"J Neuropsychol"},{"issue":"3","key":"2588_CR4","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s00412-021-10724-1","volume":"269","author":"L Cao","year":"2022","unstructured":"Cao L, Xu T, Zhao G, Ly D, Lu J, Zhao G (2022) Risk factors of impulsive-compulsive behaviors in PD pateints: a meta-analysis. J Neurology 269(3):1298\u20131315. https:\/\/doi.org\/10.1007\/s00412-021-10724-1","journal-title":"J Neurology"},{"issue":"3","key":"2588_CR5","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","volume":"91","author":"J-C Corvol","year":"2018","unstructured":"Corvol J-C, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques A-R, Bourdain F, Brandel J-P, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Lee P-C, Brice A, Vidailhet M, Elbaz A (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91(3):e189\u2013e201. https:\/\/doi.org\/10.1212\/WNL.0000000000005816","journal-title":"Neurology"},{"issue":"4","key":"2588_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.neuron.2009.01.031","volume":"61","author":"A Dagher","year":"2009","unstructured":"Dagher A, Robbins TW (2009) Personality, addiction, dopamine: insights from Parkinson\u2019s disease. Neuron 61(4):502\u2013510. https:\/\/doi.org\/10.1016\/j.neuron.2009.01.031","journal-title":"Neuron"},{"key":"2588_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.01.113","volume":"58","author":"LE De Wit","year":"2022","unstructured":"De Wit LE, Wilting I, Souverein PC, van der Pol P, Egberts TCG (2022) Impulse control disorders associated with dopaminergic drugs: a disproportionality analysis using vigibase. Eur Neuropsychopharmacol 58:30\u201338. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.01.113","journal-title":"Eur Neuropsychopharmacol"},{"key":"2588_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s10880-012-9302-7","volume":"19","author":"M Delaney","year":"2012","unstructured":"Delaney M, Leroi I, Simpson J, Overton PG (2012) Impulse control disorders in Parkinson\u2019s disease: a psychosocial perspective. J Clin Psychol Med Settings 19:338\u2013346. https:\/\/doi.org\/10.1007\/s10880-012-9302-7","journal-title":"J Clin Psychol Med Settings"},{"issue":"13","key":"2588_CR9","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/mds.23247","volume":"25","author":"A Djamshidian","year":"2010","unstructured":"Djamshidian A, Jha A, O\u2019Sullivan SS, Silveira-Moriyama L, Jacobson C, Brown P, Lees A, Averbeck BB (2010) Risk and learning in impulsive and nonimpulsive patients with Parkinson\u2019s disease. Mov Disord 25(13):2203\u20132210. https:\/\/doi.org\/10.1002\/mds.23247","journal-title":"Mov Disord"},{"issue":"1","key":"2588_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuropsychologia.2010.10.012","volume":"49","author":"A Djamshidian","year":"2011","unstructured":"Djamshidian A, O\u2019Sullivan SS, Doherty K, Lees AJ, Averbeck BB (2011a) Altruistic punishment in patients with Parkinson\u2019s disease with and without impulsive behaviour. Neuropsychologia 49(1):103\u2013107. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2010.10.012","journal-title":"Neuropsychologia"},{"issue":"9","key":"2588_CR11","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1016\/j.neuropsychologia.2011.04.026","volume":"49","author":"A Djamshidian","year":"2011","unstructured":"Djamshidian A, O\u2019Sullivan SS, Wittmann BC, Lees AJ, Averbeck BB (2011b) Novelty seeking behaviour in Parkinson\u2019s disease. Neuropsychologia 49(9):2483\u20132488. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2011.04.026","journal-title":"Neuropsychologia"},{"issue":"12","key":"2588_CR12","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 22(12):1689\u20131707. https:\/\/doi.org\/10.1002\/mds.21507","journal-title":"Mov Disord"},{"issue":"8","key":"2588_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1017\/S1092852900013778","volume":"13","author":"JM Ferrara","year":"2008","unstructured":"Ferrara JM, Stacy M (2008) Impulse-control disorders in Parkinson\u2019s disease. CNS Spectr 13(8):690\u2013698. https:\/\/doi.org\/10.1017\/S1092852900013778","journal-title":"CNS Spectr"},{"issue":"15","key":"2588_CR14","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"key":"2588_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","volume":"41","author":"M Grall-Bronnec","year":"2018","unstructured":"Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, Zreika N, Derkinderen P, Challet-Bouju G (2018) Dopamine agonists and impulse control disorders: a complex association. Drug Saf 41:19\u201375. https:\/\/doi.org\/10.1007\/s40264-017-0590-6","journal-title":"Drug Saf"},{"key":"2588_CR16","volume-title":"Verhaltenssucht: Diagnostik, Therapie, Forschung [Behavioural addiction: Diagnostics, therapy, research]","author":"SM Gr\u00fcsser","year":"2006","unstructured":"Gr\u00fcsser SM, Thalemann CN (2006) Verhaltenssucht: Diagnostik, Therapie, Forschung [Behavioural addiction: Diagnostics, therapy, research]. Huber, Bern"},{"key":"2588_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"2588_CR18","unstructured":"Hautzinger M, Keller F, K\u00fchner C (2009) Beck Depressions-Inventar Revision (BDI II). Pearson Frankfurt"},{"key":"2588_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181\u2013184. https:\/\/doi.org\/10.1136\/jnnp.55.3.181","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2588_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000337442","volume":"18","author":"S Jim\u00e9nez-Murcia","year":"2012","unstructured":"Jim\u00e9nez-Murcia S, Bove FS, Israel M, Steiger H, Fernandez-Aranda F, \u00c1lvarez-Moya E, Granero R, Penelo E, Verg\u00e9 B, Aymami M-N, Santamaria JJ, G\u00f3mez-Pna M, Moragas L, Daccidou LG, Mench\u00f3n JM (2012) Cognitive behavioral therapy for pathological gambling in Parkinson\u2019s disease: a pilot controlled study. Eur Addict Res 18:265\u2013274. https:\/\/doi.org\/10.1159\/000337442","journal-title":"Eur Addict Res"},{"key":"2588_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00702-016-1648-9","volume":"124","author":"B Leplow","year":"2017","unstructured":"Leplow B, Sepke M, Sch\u00f6nfeld R, Pohl J, Oelsner H, Latzko L, Ebersbach G (2017) Impaired learning of punishments in Parkinson\u2019s disease with and without impulse control disorder. J Neural Transm 124:217\u2013225. https:\/\/doi.org\/10.1007\/s00702-016-1648-9","journal-title":"J Neural Transm"},{"issue":"3","key":"2588_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/00207454.2011.633722","volume":"122","author":"N Limotai","year":"2012","unstructured":"Limotai N, Oyama G, Go C, Bernal O, Ong T, Moum SJ, Bhidayasiri R, Foote KD, Bowers D, Ward H, Okun MS (2012) Addiction-like manifestations and Parkinson\u2019s disease: a large single center 9-year experience. Int J Neurosci 122(3):145\u2013153. https:\/\/doi.org\/10.3109\/00207454.2011.633722","journal-title":"Int J Neurosci"},{"key":"2588_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fpsyt.2018.00465","volume":"9","author":"J Marin-Lahoz","year":"2018","unstructured":"Marin-Lahoz J, Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, Pascual-Sedano B, P\u00e9rez-P\u00e9rez J, Gironell A, Kulisevsky J (2018) Parkinson\u2019s disease: impulsivity does not cause impulse control disorders but boosts their severity. Front Psychiatry 9:465. https:\/\/doi.org\/10.3389\/fpsyt.2018.00465","journal-title":"Front Psychiatry"},{"key":"2588_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.26486","volume":"00","author":"J Mar\u00edn-Lahoz","year":"2022","unstructured":"Mar\u00edn-Lahoz J, Martinez-Horta S, Pagonabarraga J, Horta-Barba A, Aracil-Bola\u00f1os I, Bejr-kasem H, Sampedro F, Campolongo A, Kulisevsky J (2022) Predicting Impulse control disorders in Parkinson disease through incentive biomarkers. Ann Neurol 00:1\u201311. https:\/\/doi.org\/10.1002\/ana.26486","journal-title":"Ann Neurol"},{"key":"2588_CR25","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00702-018-1870-8","volume":"125","author":"A Marques","year":"2018","unstructured":"Marques A, Durif F, Fernagut P-O (2018) Impulse control disorders in Parkinson\u2019s disease. J Neural Transm 125:1299\u20131312. https:\/\/doi.org\/10.1007\/s00702-018-1870-8","journal-title":"J Neural Transm"},{"issue":"3","key":"2588_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2307\/2337038","volume":"78","author":"NJD Nagelkerke","year":"1991","unstructured":"Nagelkerke NJD (1991) A note on a general definition of the coefficient of determination. Biometrika 78(3):691\u2013692. https:\/\/doi.org\/10.2307\/2337038","journal-title":"Biometrika"},{"key":"2588_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695\u2013699. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x","journal-title":"J Am Geriatr Soc"},{"key":"2588_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.parkreldis.2019.12.009","volume":"70","author":"I Navalpotro-Gomez","year":"2020","unstructured":"Navalpotro-Gomez I, Kim J, Paz-Alonso PM, Delgado-Alvarado M, Quiroga-Varela A, Jimenez-Urbieta H, Carreiras M, Strafella AP, Cruz Rodriguez-Oroz M (2020) Disrupted salience network dynamics in Parkinson\u2019s disease patients with impulse control disorders. Parkinsonism Relat Disord 70:74\u201381. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.12.009","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"2588_CR29","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1212\/WNL.0b013e3182840678","volume":"80","author":"D Okai","year":"2013","unstructured":"Okai D, Askey-Jones S, Samuel M, O\u2019Sullivan SS, Chaudhuri KR, Martin A, Mack J, Brown RG, David AS (2013) Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 80(9):792\u2013799. https:\/\/doi.org\/10.1212\/WNL.0b013e3182840678","journal-title":"Neurology"},{"issue":"4","key":"2588_CR30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/brain\/awr003","volume":"134","author":"SS O'Sullivan","year":"2011","unstructured":"O\u2019Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, Djamshidian A, Lees AJ, Piccini P (2011) Cue-induced striatal dopamine release in Parkinson\u2019s disease-associated impulsive-compulsive behaviours. Brain 134(4):969\u2013978. https:\/\/doi.org\/10.1093\/brain\/awr003","journal-title":"Brain"},{"key":"2588_CR31","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1007\/PL00007730","volume":"245","author":"V Peto","year":"1998","unstructured":"Peto V, Jenkinson C, Fitzpatrick R (1998) PDQ-39: A review of the development, validation and application of a Parkinson\u2019s disease quality of life questionnaire and its associated measures. J Neurol 245:S10\u2013S14. https:\/\/doi.org\/10.1007\/PL00007730","journal-title":"J Neurol"},{"issue":"1","key":"2588_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocn.2013.02.032","volume":"21","author":"AL Phu","year":"2014","unstructured":"Phu AL, Xu Z, Brakoulias V, Mahant N, Fung VSC, De Moore G, Martin A, Starcevic V, Krause M (2014) Effect of impulse control disorders on disability and quality of life in Parkinson\u2019s disease patients. J Clin Neurosci 21(1):63\u201366. https:\/\/doi.org\/10.1016\/j.jocn.2013.02.032","journal-title":"J Clin Neurosci"},{"key":"2588_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11910-013-0386-8","volume":"13","author":"CC Probst","year":"2013","unstructured":"Probst CC, van Eimeren T (2013) The functional anatomy of impulse control disorders. Curr Neurol Neurosci Rep 13:386. https:\/\/doi.org\/10.1007\/s11910-013-0386-8","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2588_CR34","unstructured":"R Core Team (2021) R (Version 4.1.2) [Computer software]. https:\/\/www.R-project.org."},{"key":"2588_CR35","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1007\/s11682-019-00041-7","volume":"14","author":"S Ramdave","year":"2020","unstructured":"Ramdave S, Dawson A, Carter A, Dissanayaka NNW (2020) Unmasking neurobiological commonalities between addictive disorders and impulse control disorders in Parkinson\u2019s disease. Brain Imaging Behav 14:2785\u20132798. https:\/\/doi.org\/10.1007\/s11682-019-00041-7","journal-title":"Brain Imaging Behav"},{"issue":"3","key":"2588_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","volume":"7","author":"S Schade","year":"2020","unstructured":"Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: An updated proposal including opicapone and safinamide. Mov Disord Clin Pract 7(3):343\u2013345. https:\/\/doi.org\/10.1002\/mdc3.12921","journal-title":"Mov Disord Clin Pract"},{"key":"2588_CR37","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00115-010-3010-z","volume":"81","author":"A Storch","year":"2010","unstructured":"Storch A, Odin P, Trender-Gerhard I, Fuchs G, Reifschneider G, Ray Chaudhuri K, Jost WH, Ebersbach G (2010) Non-motor symptoms questionnaire and scale for Parkinson\u2019s disease: cross-cultural adaptation into the german language. Nervenarzt 81:980\u2013985. https:\/\/doi.org\/10.1007\/s00115-010-3010-z","journal-title":"Nervenarzt"},{"key":"2588_CR38","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1136\/jnnp.2003.024885","volume":"75","author":"R Tomer","year":"2004","unstructured":"Tomer R, Aharon-Peretz J (2004) Novelty seeking and harm avoidance in Parkinson\u2019s disease: Effects of asymmetric dopamine deficiency. J Neurol Neurosurg Psychiatry 75:972\u2013975. https:\/\/doi.org\/10.1136\/jnnp.2003.024885","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"15","key":"2588_CR39","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25(15):2649\u20132653. https:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"issue":"8","key":"2588_CR40","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/archneur.64.8.1089","volume":"64","author":"V Voon","year":"2007","unstructured":"Voon V, Fox SH (2007) Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64(8):1089\u20131096. https:\/\/doi.org\/10.1001\/archneur.64.8.1089","journal-title":"Arch Neurol"},{"issue":"1","key":"2588_CR41","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuron.2009.12.027","volume":"65","author":"V Voon","year":"2010","unstructured":"Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH, Dolan RJ, Hallett M (2010a) Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 65(1):135\u2013142. https:\/\/doi.org\/10.1016\/j.neuron.2009.12.027","journal-title":"Neuron"},{"key":"2588_CR42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00213-009-1697-y","volume":"207","author":"V Voon","year":"2010","unstructured":"Voon V, Reynolds B, Brezing C, Gallea C, Skaljic M, Ekanayake V, Fernandez H, Potenza MN, Dolan RJ, Hallett M (2010b) Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology 207:645\u2013659. https:\/\/doi.org\/10.1007\/s00213-009-1697-y","journal-title":"Psychopharmacology"},{"key":"2588_CR43","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","volume":"133","author":"D Weintraub","year":"2017","unstructured":"Weintraub D, Claassen DO (2017) Impulse control and related disorders in Parkinson\u2019s disease. Int Rev Neurobiol 133:679\u2013717. https:\/\/doi.org\/10.1016\/bs.irn.2017.04.006","journal-title":"Int Rev Neurobiol"},{"key":"2588_CR44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000341996","volume":"11","author":"D Weintraub","year":"2013","unstructured":"Weintraub D, Nirenberg MJ (2013) Impulse control and related disorders in Parkinson\u2019s disease. Neurodegener Dis 11:63\u201371. https:\/\/doi.org\/10.1159\/000341996","journal-title":"Neurodegener Dis"},{"issue":"7","key":"2588_CR45","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archneur.63.7.969","volume":"63","author":"D Weintraub","year":"2006","unstructured":"Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63(7):969\u2013973. https:\/\/doi.org\/10.1001\/archneur.63.7.969","journal-title":"Arch Neurol"},{"issue":"10","key":"2588_CR46","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"24","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord 24(10):1461\u20131467. https:\/\/doi.org\/10.1002\/mds.22571","journal-title":"Mov Disord"},{"issue":"5","key":"2588_CR47","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67(5):589\u2013595. https:\/\/doi.org\/10.1001\/archneurol.2010.65","journal-title":"Arch Neurol"},{"issue":"2","key":"2588_CR48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","volume":"80","author":"D Weintraub","year":"2013","unstructured":"Weintraub D, Papay K, Siderowf A (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 80(2):176\u2013180. https:\/\/doi.org\/10.1212\/WNL.0b013e31827b915c","journal-title":"Neurology"},{"issue":"2","key":"2588_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, David AS, Evans AH, Grant JE, Stacy M (2015) Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov Disord 30(2):121\u2013127. https:\/\/doi.org\/10.1002\/mds.26016","journal-title":"Mov Disord"},{"issue":"7","key":"2588_CR50","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/acn3.51569","volume":"9","author":"D Weintraub","year":"2022","unstructured":"Weintraub D, Posavi M, Fontanillas P, Tropea TF, Mamikonyan E, Suh E, Trojanowski JQ, Cannon P, Van Deerlin VM, 23andMe Research Team, Chen-Plotkin AS (2022) Genetic prediction of impulse control disorders in Parkinson\u2018s disease. Ann Clin Transl Neurol 9(7):936\u2013949. https:\/\/doi.org\/10.1002\/acn3.51569","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02588-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-023-02588-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02588-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T14:06:06Z","timestamp":1675692366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-023-02588-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2588"],"URL":"https:\/\/doi.org\/10.1007\/s00702-023-02588-8","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B. Leplow has nothing to disclose. D. Renftle has nothing to disclose. M. Thomas has nothing to disclose. K. Michaelis has nothing to disclose. S. Solbrig has nothing to disclose. W. Maetzler reports grant from the European Union, the German Federal Ministry of Education of Research, German Research Council, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Lundbeck, Sivantos and Janssen, outside the submitted work. He received speaker honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Neuro-Kolleg Online-Live, R\u00f6lke Pharma, Takeda and UCB, was invited to Advisory Boards of Abbvie, Biogen, Kyowa Kirin, Lundbeck and Market Access & Pricing Strategy GmbH, is an advisory board member of the Critical Path for Parkinson's Consortium, and an editorial board member of Geriatric Care. He serves as the co-chair of the MDS Technology Task Force. D. Berg reports grants from Janssen Research and Development, a division of Janssen Pharmaceutica N.V. related to the conduct of this study; grants from German Research Foundation (DFG), German Parkinson\u2019s Disease Association (dPV), German Ministry for Education and Research (BMBF), Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck, Damp foundation, outside the submitted work. She received speaker honoraria from AbbVie, Biogen, BIAL, UCB Pharma GmbH Zambon, Desitin and was invited to Advisory Boards for Biogen, BIAL, UCB Pharma GmbH, Zambon. I. Liepelt-Scarfone reports grants from Janssen Research and Development, a division of Janssen Pharmaceutica N.V. related to the conduct of this study; grants from the Michael J. Fox Foundation during the conduct of the study, European Commission, H2020-TWINN-2015, International Parkinson Fonds (Deutschland) GmbH (IPD), Novartis, German Ministry for Education and Research (BMBF), outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}